India · Delayed Price · Currency is INR Marksans Pharma Statistics
Total Valuation
Marksans Pharma has a market cap or net worth of INR 82.36 billion. The enterprise value is 79.27 billion.
| Market Cap | 82.36B |
| Enterprise Value | 79.27B |
Important Dates
The last earnings date was Thursday, February 5, 2026.
| Earnings Date | Feb 5, 2026 |
| Ex-Dividend Date | Aug 1, 2025 |
Share Statistics
| Current Share Class | 453.16M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.11% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 43.87% |
| Owned by Institutions (%) | 11.92% |
| Float | 214.46M |
Valuation Ratios
The trailing PE ratio is 22.86 and the forward PE ratio is 17.48.
| PE Ratio | 22.86 |
| Forward PE | 17.48 |
| PS Ratio | 2.94 |
| PB Ratio | 3.04 |
| P/TBV Ratio | 3.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 22.00 |
| EV / Sales | 2.83 |
| EV / EBITDA | 15.27 |
| EV / EBIT | 18.39 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.64 |
| Debt / FCF | n/a |
| Interest Coverage | 20.29 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 13.76% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 15.24M |
| Profits Per Employee | 1.96M |
| Employee Count | 1,840 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Marksans Pharma has paid 1.15 billion in taxes.
| Income Tax | 1.15B |
| Effective Tax Rate | 24.10% |
Stock Price Statistics
The stock price has decreased by -28.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -28.43% |
| 50-Day Moving Average | 178.68 |
| 200-Day Moving Average | 202.79 |
| Relative Strength Index (RSI) | 55.09 |
| Average Volume (20 Days) | 51,443 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marksans Pharma had revenue of INR 28.03 billion and earned 3.60 billion in profits. Earnings per share was 7.95.
| Revenue | 28.03B |
| Gross Profit | 15.37B |
| Operating Income | 4.31B |
| Pretax Income | 4.77B |
| Net Income | 3.60B |
| EBITDA | 4.92B |
| EBIT | 4.31B |
| Earnings Per Share (EPS) | 7.95 |
Balance Sheet
The company has 6.67 billion in cash and 3.32 billion in debt, with a net cash position of 3.35 billion.
| Cash & Cash Equivalents | 6.67B |
| Total Debt | 3.32B |
| Net Cash | 3.35B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 27.14B |
| Book Value Per Share | 59.37 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 54.83%, with operating and profit margins of 15.38% and 12.85%.
| Gross Margin | 54.83% |
| Operating Margin | 15.38% |
| Pretax Margin | 17.00% |
| Profit Margin | 12.85% |
| EBITDA Margin | 17.56% |
| EBIT Margin | 15.38% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 0.45%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 0.45% |
| Dividend Growth (YoY) | 33.33% |
| Years of Dividend Growth | 3 |
| Payout Ratio | n/a |
| Buyback Yield | -0.11% |
| Shareholder Yield | 0.35% |
| Earnings Yield | 4.37% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.
| Last Split Date | Mar 11, 2008 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |